Study tests microRNA markers in worsened liver cirrhosis
Part of Digestive system clinical trials.
This study looks at microRNA (tiny molecules in blood) to better understand what’s happening during sudden worsening of cirrhosis. It may help doctors recognize and monitor decompensated cirrhosis more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis confirmed by tests or by common signs like portal hypertension and poor liver function
- You are either admitted within 48 hours for a sudden worsening episode, or you are followed as an outpatient with stable cirrhosis
- Your worsening episode may include jaundice, confusion from liver disease, fluid buildup/ascites, bleeding, kidney failure or low sodium, or lab changes showing reduced liver function
- You (or your decision-maker, if you can’t decide) agree to join after being informed
- You are not under legal protection/guardianship or curatorship
- You are not pregnant and do not have certain past or current cancers of the liver/bile ducts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your body uses protein in your muscles when you have cirrhosis (a scarred liver). It uses a special “tracer” method (a substance that can be tracked) and may help researchers better understand muscle loss in people with milder cirrhosis.
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
This study is exploring a new way to predict how liver cirrhosis will progress. It may help doctors better understand and manage the condition.
This study looks at new blood markers to better predict recovery in patients hospitalized for complications of cirrhosis (like fluid buildup, confusion, or bleeding). You may qualify if you were recently hospitalized for these issues and are expected to go home soon.
This trial tests umbilical-cord stem cells to see if they can improve outcomes in people with decompensated (worsening) cirrhosis. You may be considered if your liver disease is moderate to severe (MELD 15–30) and you do not have certain high-risk problems right now.
This trial compares new scoring tools to predict outcomes in people with liver cirrhosis who are hospitalized for sudden worsening (like fluid buildup, confusion, or bleeding). It aims to find which score works best to guide care.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.